IFNG and cancer: The TMB/neoantigen/IFN-γ pathway is a well understood cancer pathway that results in PD-L1 upregulation, supported by the finding that even partial loss of MMR significantly correlates with increased PD-L1 expression suggesting a therapeutic vulnerability in HRD TNBC (6).